Vontobel Holding Ltd. Sells 1,146 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Vontobel Holding Ltd. reduced its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 3.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 37,398 shares of the biotechnology company’s stock after selling 1,146 shares during the period. Vontobel Holding Ltd.’s holdings in Rocket Pharmaceuticals were worth $691,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in Rocket Pharmaceuticals by 31.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock valued at $68,000 after buying an additional 764 shares during the period. SG Americas Securities LLC bought a new stake in shares of Rocket Pharmaceuticals during the third quarter valued at approximately $113,000. Dana Investment Advisors Inc. boosted its holdings in shares of Rocket Pharmaceuticals by 4.4% in the second quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 586 shares during the period. Mirador Capital Partners LP bought a new position in Rocket Pharmaceuticals in the third quarter worth approximately $310,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Rocket Pharmaceuticals by 30.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,092 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 3,995 shares during the period. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Trading Down 6.4 %

Shares of Rocket Pharmaceuticals stock opened at $17.62 on Tuesday. The firm’s 50 day simple moving average is $18.52 and its two-hundred day simple moving average is $21.08. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -6.14 and a beta of 1.09. Rocket Pharmaceuticals, Inc. has a 12-month low of $15.98 and a 12-month high of $32.53. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.05.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.02). During the same period last year, the firm posted ($0.82) earnings per share. Analysts predict that Rocket Pharmaceuticals, Inc. will post -2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on RCKT shares. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, September 17th. Canaccord Genuity Group reiterated a “buy” rating and set a $38.00 target price on shares of Rocket Pharmaceuticals in a report on Monday, September 30th. Chardan Capital reissued a “buy” rating and set a $62.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Finally, Scotiabank started coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.75.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.